FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
29/08/2022
Voltar para busca
Dado oficial do USPTO
TREAT
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
TREAT
ST13
US500000079290962Classe
1, 5, 9, 10, 42, 44
Pedido
79290962
Registro
6661741
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
40
Atualização mais recente
29/08/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 9, 10, 42, 44
Data de depósito
29/05/2020
Data de registro
08/03/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
08/03/2022
Última transação
08/03/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
33
Localização do titular
CH
Examinador
MESSICK, TABITHA LEE
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Ichnos Sciences SA
Representantes
Jeffrey H. Greger Hauptman Ham, LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 9Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical products used in industry and science as well as in agriculturehorticulture and forestryparticularly laboratory chemicalsbiochemicals in the nature of antibodiestrimeric antibodies and derivatives thereofall for use in the development or manufacture of immunological reagents for industrial and scientific use; laboratory chemicalsbiochemicals in the nature of antibodiestrimeric antibodies and derivatives thereof for laboratoriesdiagnostics and analytics for scientific or research use; chemical preparations for industrial and scientific use
Classe 5
Medical preparationsantibodiestrimeric antibodies and derivatives thereoffor the treatment of cancerallergiesasthmaautoimmune diseasesinflammationgraft versus host diseasesinflammationtransplant rejectioninfectious diseasesbone diseasesheart diseasesendocrine diseaseseye diseasesintestinal diseases and neurological diseasesin the form of parenteralintravitrealintra-peritoneal and aerosol therapies; medical preparationsantibodies for diagnostic or therapeutic use and for use in assay
Classe 9
Scientificweighingmeasuringcheckingsupervision and teaching apparatus and instruments for scientific laboratory research in the field of antibodiestrimeric antibodies and derivatives thereoflaboratory equipment for purifyingdetecting and analysing antibodiestrimeric antibodies and derivatives thereof
Classe 10
Medical apparatus and instruments in the nature of medical devices and instruments to purifydetect and analyse antibodiestrimeric antibodies and derivatives thereof from patient samples who have a respiratory conditions; spirometers; medical devices in the nature of medical devices and instruments to purifydetect and analyse antibodiestrimeric antibodies and derivatives thereof from patient samples from body fluid samples; means of administration of medicinal products such as inhalers and nasal spray nebulizers; Medical apparatus and instruments in the nature of syringes for medical purposes; medical devices and instruments to purifydetect and analyse antibodiestrimeric antibodies and derivatives thereof from patient blood samples; diagnostic apparatus for medical use for detection of cancer
Classe 42
Medical researchlaboratory research in the field of antibodiestrimeric antibodies and derivatives thereof; product development in the field of medicinesantibodiestrimeric antibodies and derivatives thereof; analysis of antibodiestrimeric antibodies and derivatives thereof in the nature of industrial analysis; contract research services in the field of antibodiestrimeric antibodies and derivatives thereof
Classe 44
Medical servicesmedical clinicsmedical assistancepharmacy advice all in the field of antibodiestrimeric antibodies and derivatives thereof; hygienic and beauty care for human beings or animals; veterinary services; agriculturehorticulture and forestry servicescompost spreading; providing information in the field of antibodiestrimeric antibodies and derivatives thereof
Publicações
Histórico de despachos e eventos da marca no USPTO.
40 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
05/08/2022
FIMP
FINAL DISPOSITION PROCESSED
05/08/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/06/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
08/03/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
29/01/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/01/2022
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/01/2022
LOPR
LETTER OF PROTEST EVIDENCE REVIEWED-NO FURTHER ACTION TAKEN
30/12/2021
GPNX
NOTIFICATION PROCESSED BY IB
26/12/2021
LOPT
LETTER OF PROTEST EVIDENCE FORWARDED
22/12/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/12/2021
PUBO
PUBLISHED FOR OPPOSITION
21/12/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/12/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/12/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/12/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/11/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
11/11/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
11/11/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
11/11/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
11/11/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/10/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/10/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/10/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
14/04/2021
GNRT
NON-FINAL ACTION E-MAILED
14/04/2021
CNRT
NON-FINAL ACTION WRITTEN
14/04/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
26/03/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/03/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
25/03/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/11/2020
RFNT
REFUSAL PROCESSED BY IB
19/10/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
25/09/2020
RFRR
REFUSAL PROCESSED BY MPU
25/09/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
03/09/2020
CNRT
NON-FINAL ACTION WRITTEN
02/09/2020
DOCK
ASSIGNED TO EXAMINER
31/08/2020
MAFR
APPLICATION FILING RECEIPT MAILED
11/08/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/08/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/08/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TREAT ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.